Extended Data Fig. 2: Heatmap illustrates the network proximity between molecular targets of 21 ongoing repurposable AD drugs and 37 AD disease modules. | Nature Aging

Extended Data Fig. 2: Heatmap illustrates the network proximity between molecular targets of 21 ongoing repurposable AD drugs and 37 AD disease modules.

From: Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease

Extended Data Fig. 2: Heatmap illustrates the network proximity between molecular targets of 21 ongoing repurposable AD drugs and 37 AD disease modules.

These drugs could target amyloid, tau, or both amyloid and tau pathologies or their related pathways in in vitro or in vivo mouse models or in patients with AD. We built three AD network modules by assembling experimentally validated (seed) genes in amyloidosis (amyloid), tauopathy (tau) and AD (characterized by both amyloid and tau). In addition, we also built disease modules from 34 differentially expressed gene (DEG) sets derived from transcriptomics data (including microarray and bulk RNA-sequencing) from AD genetic mouse.

Back to article page